Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
  • Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.
     
  • Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new cases in 2020 in Europe alone1
     
  • Sandoz has been developing and providing oncology medicines for over 30 years, to expand access to and increase affordability of high quality medicines
     

Basel, December 22, 2021 — Sandoz, a global …

/by
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
  • Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.  
     
  • Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers1,2
     
  • Sandoz continues to build on leading generic and biosimilar oncology portfolio to increase patient access and contribute to sustainability of healthcare systems

…

/by
1/12/2022 : 40th Annual J.P. Morgan Healthcare Conference

View the live Webcast

/by
4/27/2022 : 2022 Annual General Meeting

/by
5/11/2022 : Alcon’s First Quarter 2022 Earnings Conference Call


View the live Webcast

/by
8/10/2022 : Alcon’s Second Quarter 2022 Earnings Conference Call


View the live Webcast

/by
11/16/2022 : Alcon’s Third Quarter 2022 Earnings Conference Call


View the live Webcast

/by
11/16/2022 : Alcon’s Third Quarter 2022 Earnings Conference Call
/by